In addition, studies of colorectal and gastric carcinoma, glioblastoma, and esophageal adenocarcinoma have all demonstrated heterogeneity of LGR5 expression and shown that high LGR5 levels are associated with worse outcomes (Becker et al., 2010; Simon et al., 2012; Wu et al., 2012; Nakata et al., 2013). Here, LGR5 is linked to esophageal adenocarcinoma.